Helius Therapeutics Enters Groundbreaking Cannabis Sleep Study
Helius Therapeutics, a trailblazer in New Zealand's medicinal cannabis sector, is embarking on an exciting journey to explore the potential of cannabis as a sleep aid. The company has signed a pivotal supply agreement with the University of Auckland for a Phase 2 clinical trial, which aims to investigate the effectiveness of cannabis-derived medicine for patients struggling with chronic back pain and sleep disturbances.
Understanding the CPS Trial's Importance
Known as the CPS Trial (Cannabis, Pain, Sleep), this innovative study will unfold over seven months, with participation from prominent institutions including Tauranga Hospital and the University of Otago. Lead investigator Dr. Saad Anis, an experienced pain medicine physician, emphasized the urgent need for credible research, noting that over 20% of New Zealand adults endure chronic non-cancer pain, often accompanied by sleep issues. "Many patients express interest in cannabis-derived medicines, yet definitive evidence is scarce, making it a challenge for healthcare providers to recommend them with confidence," he remarked.
The Mechanics of the Trial
Participants will engage in a randomized, double-blind, placebo-controlled crossover study, taking the study medicine at bedtime for three months, followed by a placebo for an additional three months. To track the participants’ sleep quality, their sleep patterns will be monitored meticulously using wrist-worn devices. The primary outcome is assessed through the Insomnia Severity Index, complemented by measures of sleep patterns derived from actigraphy.
The Significance of High-Quality Evidence
The trial, supported by the University of Auckland and an Australian and New Zealand College of Anaesthetists novice investigator grant, aims to produce important data that could reshape the landscape of medicinal cannabis. "This independent study is a crucial step forward for the sector, potentially improving general practice prescriptions and enhancing trust in cannabis therapies," noted Helius Therapeutics CEO Zoë Reece. As the medicinal cannabis sector evolves, effective clinical trials like CPS are viewed as building blocks towards validating these therapies.
Growing Demand and Future Prospects
As per Health New Zealand's data, medicinal cannabis dispensings have skyrocketed from 4,875 in 2020 to an impressive 389,668 in 2025. This surge highlights the increasing demand for medicinal cannabis as awareness and acceptance grow. Helius Therapeutics is keenly aware of this potential, demonstrating dedication to ensuring reliable and high-quality cannabis products. With over 80 products meeting the rigorous standards of New Zealand's Medicinal Cannabis Scheme, the outlook remains buoyant.
What’s Next for the CPS Trial?
The results of this pioneering CPS Trial are expected to be published in early 2028, with anticipation high amongst both the medical community and patients alike. Continued research will not only empower practitioners with data but also open avenues for patients to access cannabis therapies that genuinely improve their quality of life.
Join the Conversation
As the debate around medicinal cannabis evolves, it is crucial for industry stakeholders and patients to stay informed and engaged. Trials like the CPS could redefine how cannabis is perceived and utilized in healthcare, leading to more informed decisions in medical practices. Let's keep sharing these impactful developments!
Write A Comment